A 31-amino-acid GLP-1 analog with 97% homology to native GLP-1. The first long-acting GLP-1 receptor agonist, enabling once-daily dosing. FDA-approved as Victoza (diabetes) and Saxenda (obesity). Paved the way for semaglutide.
Liraglutide is a 31-amino-acid GLP-1 analog that was the first long-acting incretin mimetic to reach the market. Developed by Novo Nordisk and approved in 2010, it demonstrated that GLP-1 receptor agonism could be a viable therapeutic strategy for both Type 2 diabetes and obesity.
Liraglutide has 97% sequence homology to native GLP-1 (one amino acid change: Lys34→Arg34) plus a C16 fatty acid (palmitic acid) attached to Lys26 via a glutamic acid spacer. This fatty acid enables albumin binding, extending the half-life from 2 minutes (native GLP-1) to approximately 13 hours — enabling once-daily injection.
Liraglutide was Novo Nordisk's first long-acting GLP-1 receptor agonist and the direct predecessor to semaglutide. Approved as Victoza for Type 2 diabetes in 2010 and as Saxenda for weight management in 2014, liraglutide proved that GLP-1-based therapy could produce clinically meaningful weight loss — paving the way for semaglutide's later, more dramatic results. The LEADER trial (2016) established that liraglutide reduces cardiovascular events in patients with Type 2 diabetes, making it the first GLP-1 agonist with proven CV benefit.
Structurally, liraglutide achieves its extended half-life (~13 hours, enabling once-daily dosing) through a C16 fatty acid (palmitic acid) attached to Lys26 via a glutamic acid spacer. This fatty acid enables albumin binding in the bloodstream, slowing renal clearance. Semaglutide improved on this approach with a C18 fatty diacid and additional DPP-4 resistance modifications, achieving a ~7-day half-life and the shift from daily to weekly dosing.
While semaglutide has largely supplanted liraglutide for new prescriptions, Saxenda remains widely prescribed for weight management and is an important option for patients who prefer daily dosing or who experience better GI tolerability with the shorter-acting formulation.
Liraglutide's mechanism is identical to native GLP-1 and semaglutide — it binds and activates the GLP-1 receptor, a Gs-coupled GPCR. The clinical differences between liraglutide and semaglutide are pharmacokinetic, not pharmacodynamic: liraglutide's C16 fatty acid provides sufficient albumin binding for once-daily dosing, while semaglutide's C18 fatty diacid provides stronger albumin affinity for once-weekly dosing.
| Pathway | Effect | Significance |
|---|---|---|
| Insulin secretion | Glucose-dependent β-cell stimulation | Lowers blood sugar only when glucose is elevated — low hypoglycemia risk |
| Glucagon suppression | Reduces α-cell glucagon output | Prevents excessive hepatic glucose production |
| Gastric emptying | Slows food transit from stomach | Reduces postprandial glucose spikes and increases satiety |
| Appetite suppression | CNS GLP-1R activation in hypothalamus | Average 8% weight loss (Saxenda 3.0 mg dose) |
| Cardioprotection | Reduces atherosclerosis and inflammation | 13% reduction in MACE in LEADER trial |
| Study | Design | Findings | Level |
|---|---|---|---|
| LEAD program | Phase III, T2D, multiple trials | Superior HbA1c reduction vs sulfonylureas and comparable to insulin; significant weight loss | Level I |
| SCALE program | Phase III, obesity, n=3,731 | 8% mean weight loss at 3.0 mg dose over 56 weeks (Saxenda) | Level I |
| LEADER trial | Phase III, CV outcomes, n=9,340 | 13% reduction in major adverse cardiovascular events (MACE) vs placebo | Level I |
| Pediatric obesity | Phase III | Approved for adolescents (12-17) with obesity. Significant BMI reduction vs placebo. | Level I |
GI side effects: Nausea (occurring in ~25-40% of patients), vomiting, and diarrhea are the most common adverse effects. The once-daily dosing means patients experience a daily peak-and-trough cycle of GLP-1 receptor activation, which some patients tolerate better and others worse compared to the more sustained levels produced by weekly semaglutide.
Thyroid C-cell tumors: Same boxed warning as all GLP-1 agonists — rodent studies showed thyroid C-cell tumors. Contraindicated with MTC or MEN2 history.
Pancreatitis: Rare cases of acute pancreatitis reported. Same monitoring recommendations as the GLP-1 class.
Cardiovascular benefit: The LEADER trial demonstrated a 13% reduction in MACE (major adverse cardiovascular events) — making liraglutide one of the few diabetes drugs with proven cardiovascular benefit.
Weight loss magnitude: Saxenda (3.0 mg daily) produces approximately 5-8% body weight loss — meaningful but substantially less than semaglutide 2.4 mg weekly (15-17%) or tirzepatide (20-22%). This difference in efficacy, combined with the convenience of weekly vs daily dosing, is the primary reason semaglutide has become the dominant GLP-1 therapy.
| Jurisdiction | Status |
|---|---|
| FDA | Approved: Victoza (T2D, 2010), Saxenda (obesity, 2014) |
| EMA | Approved for T2D and weight management |
| Historical | First long-acting GLP-1 agonist. Proof-of-concept for the entire class. |
| Feature | Liraglutide | Semaglutide |
|---|---|---|
| Half-life | ~13 hours (daily injection) | ~7 days (weekly injection) |
| Weight loss | ~8% (SCALE trials) | ~15-17% (STEP trials) |
| Fatty acid | C16 palmitic acid | C18 fatty diacid |
| DPP-4 resistance | Lys34→Arg34 only | Ala8→Aib (steric shield) |
| Dosing | Once daily | Once weekly |
| Market position | First-to-market GLP-1 | Market leader |